Lanthanum carbonate (Fosrenol®) efficacy and tolerability in the treatment of hyperphosphatemic patients with end-stage renal disease

Chiang, S S; Chen, J B; Yang, Weipeng

doi:10.5414/cnp63461

Cited by 45 publications

(37 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Multiple treatment comparison network: proportion of patients achieving phosphate control [15 RCTs; [31,32,33,34,35,36,37,38,39,40,41,42,43,44,45]]. Relative effectiveness compared to placebo: proportion achieving phosphate control.…”

Section: Methodsmentioning

confidence: 99%

Management of Hyperphosphataemia in Chronic Kidney Disease: Summary of National Institute for Health and Clinical Excellence (NICE) Guideline

et al. 2013

View full text Add to dashboard Cite

Bone disease and ectopic calcification are the two main consequences of hyperphosphataemia of chronic kidney disease (CKD). Observational studies have demonstrated that hyperphosphataemia in CKD is associated with increased mortality. Furthermore, the use of phosphate binders in dialysis patients is associated with significantly lower mortality. The UK Renal Registry data show significant underachievement of phosphate targets in dialysis patients. It is believed to be due to wide variation in how management interventions are used. The National Institute for Health and Clinical Excellence (NICE) has developed a guideline on the management of hyperphosphataemia in CKD. This is based on the evidence currently available using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology. This review outlines the recommendations including research recommendations and discusses methodology, rationale and challenges faced in developing this guideline and the health economic model used to assess the cost-effectiveness of different phosphate binders.

show abstract

Section: Methodsmentioning

confidence: 99%

Management of Hyperphosphataemia in Chronic Kidney Disease: Summary of National Institute for Health and Clinical Excellence (NICE) Guideline

et al. 2013

View full text Add to dashboard Cite

show abstract

“…Preclinical studies have shown that lanthanum binds phosphate equally well at all relevant pH levels throughout the gastrointestinal tract [2, 3]. In short-term, placebo-controlled clinical trials, lanthanum carbonate was significantly more effective than placebo in reducing serum phosphate levels, with a safety profile similar to that of placebo and a rapid onset of action within 1–2 weeks [4,5,6]. In a 6-month, treat-to-target, comparative study of lanthanum carbonate versus calcium carbonate, the efficacy and safety profile of the two agents were similar [7].…”

Section: Introductionmentioning

confidence: 99%

Long-Term Efficacy and Safety Profile of Lanthanum Carbonate: Results for up to 6 Years of Treatment

Hutchison

Barnett²,

Krause³

et al. 2008

Nephron Clin Pract

103

View full text Add to dashboard Cite

Background/Aims: Lanthanum carbonate (LC, FOSRENOL®) is an effective phosphate binder for which tolerability and a safety profile have been reported in haemodialysis patients. Patients from previous studies entered a 2-year extension, enabling assessment of efficacy and safety for up to 6 years of LC monotherapy. Methods: Patients from four previous trials entered this study. Results: Ninety-three patients started the extension, with 22 entering a sixth year of LC treatment. Two-thirds of all patients received LC doses of 2,250 or 3,000 mg/day. Reductions in serum phosphate and calcium × phosphate product were maintained for up to 6 years. There were no new or unexpected adverse events (AEs), and no increase in the incidence of events with increasing treatment exposure. Over the complete duration of therapy, treatment-related AEs occurred in 25.8% of patients and were primarily gastrointestinal in nature. No clinically relevant changes in liver function tests were observed and there was no evidence of adverse effects on the liver, bone or the central nervous system. Conclusions: LC monotherapy was effective and well tolerated for up to 6 years with no evidence of safety concerns or increased frequency of AEs.

show abstract

“…Both short-and long-term clinical studies have demonstrated efficacy and an acceptable safety profile (15)(16)(17)(18). This study was designed to evaluate the efficacy and safety of lanthanum carbonate for use in patients with CKD stages 3 and 4, a population in which randomized, controlled clinical trials of phosphate binders are sparse (19).…”

mentioning

confidence: 99%

Lanthanum Carbonate Reduces Phosphorus Burden in Patients with CKD Stages 3 and 4

Sprague¹,

Abboud²,

Qiu³

et al. 2009

Clinical Journal of the American Society of Nephrology

View full text Add to dashboard Cite

show abstract

Lanthanum carbonate (Fosrenol®) efficacy and tolerability in the treatment of hyperphosphatemic patients with end-stage renal disease

Cited by 45 publications

References 0 publications

Management of Hyperphosphataemia in Chronic Kidney Disease: Summary of National Institute for Health and Clinical Excellence (NICE) Guideline

Management of Hyperphosphataemia in Chronic Kidney Disease: Summary of National Institute for Health and Clinical Excellence (NICE) Guideline

Long-Term Efficacy and Safety Profile of Lanthanum Carbonate: Results for up to 6 Years of Treatment

Lanthanum Carbonate Reduces Phosphorus Burden in Patients with CKD Stages 3 and 4

Contact Info

Product

Resources

About